Table 2.
item | Round 1 % |
Round 2 % |
Round 3 % |
AUS-NZ | UK | ||
---|---|---|---|---|---|---|---|
AUS-NZ: Australia and New Zealand, UK: the United Kingdom, *: Essential, NRC: did not reach consensus, NE: not essential, N/A: not available ECG: electrocardiogram, PiCCO: pulse contour cardiac output, CO: cardiac output, CI: cardiac index, SVV: stroke volume variation, SVRI: systemic vascular resistance index, PAP: pulmonary artery pressure, ECMO: extracorporeal membrane oxygenation, CPAP: continuous positive airway pressure, PEEP: positive end expiratory pressure, EPAP: expiratory positive airway pressure, PS: pressure support, IPAP: Inspiratory Positive Airway Pressure, SIMV: synchronised intermittent mandatory ventilation, STEMI: ST elevation myocardial infarction, NSTEMI: non-ST elevation myocardial infarction, VAP: ventilator-associated pneumonia, MODS: multiple organ dysfunction syndrome, COPD: chronic obstructive pulmonary disease, PVC: premature ventricular contraction, ALT: alanine aminotransferase, LDH: lactate dehydrogenase, FEV1: forced expiratory volume in one second, FVC: forced vital capacity, CAM-ICU: confusion assessment method for the intensive care unit, CT: computed tomography, MRI: magnetic resonance imaging, ASIA: American Spinal Cord Injury Association, HCO3: bicarbonate, PaCO2: partial pressure of arterial carbon dioxide, PaO2: partial pressure of arterial oxygen, SPO2: peripheral capillary oxygen saturation, SaO2: arterial oxygen saturation, pH: potential of hydrogen, SvO2: mixed venous oxygen saturation, FiO2: fraction of inspired oxygen ACBT: active cycle of breathing technique, FET: forced expiratory technique, MRC: Medical Research Council, 6MWT: 6-minute walk test, EQ-5D: EuroQol 5 Dimension, AQoL: Assessment of Quality of Life | |||||||
A physiotherapist is aware or has knowledge of | |||||||
Key literature that guides evidence-based physiotherapy practice in critical care settings | |||||||
Key literature that guides evidence-based physiotherapy practice in critical care settings | 100 | ― | ― | * | NRC | ||
The actions and implications for physiotherapy of the following medications | |||||||
Analgesia | 93 | ― | ― | * | N/A | ||
Anti-arrhythmics (e.g. amiodarone, digoxin) | 96 | ― | ― | * | * | ||
Anti-hypertensives (e.g. beta-blockers, hydralazine) | 98 | ― | ― | * | * | ||
Bronchodilators | 89 | ― | ― | * | * | ||
Calcium channel blockers | 87 | ― | ― | NRC | NE | ||
Sedation and neuromuscular paralyzing agents | 100 | ― | ― | * | * | ||
Vasopressors/inotropes (e.g. dobutamine, milrinone, adrenaline, dopamine, noradrenaline) | 100 | ― | ― | * | * | ||
Methods for advanced hemodynamic monitoring, can interpret the measurements and understands the implications for physiotherapy of | |||||||
Implanted or external pacemakers, and determine the presence of pacing on ECG | 96 | ― | ― | * | NRC | ||
PiCCO measurements (e.g. CO, CI, SVV, SVRI etc.) | 83 | ― | ― | NE | NE | ||
Pulmonary arterial catheter measurements (e.g. CO, CI, SVRI, PAP, etc.) | 85 | ― | ― | NE | NE | ||
A physiotherapist can understand | |||||||
Equipment (including recognition of equipment), can use/safely apply or handle equipment, understands the implications for physiotherapy of | |||||||
Arterial lines | 100 | ― | ― | * | * | ||
Central venous catheters | 98 | ― | ― | * | * | ||
ECMO | 74 | ― | ― | NE | NE | ||
Endotracheal tubes and tracheostomy | 100 | ― | ― | * | * | ||
Indwelling urinary catheters | 91 | ― | ― | * | * | ||
Intercostal catheters | 100 | ― | ― | * | * | ||
Intra-aortic balloon pump | 89 | ― | ― | NRC | NE | ||
Intracranial pressure (ICP) monitors and extra-ventricular drains (EVD) | 91 | ― | ― | * | NE | ||
Nasogastric tubes | 98 | ― | ― | * | * | ||
Oxygen therapy devices | 100 | ― | ― | * | * | ||
Vascath/hemodialysis/continuous veno-venous hemodiafiltration | 94 | ― | ― | * | * | ||
Wound drains | 100 | ― | ― | * | * | ||
The key principles of providing the following differing modes of mechanical/assisted ventilation including | |||||||
Airway Pressure Release Ventilation (APRV) | 76 | ― | ― | NE | NE | ||
Assist-control | 98 | ― | ― | * | NRC | ||
BiLevel | 83 | ― | ― | * | * | ||
CPAP | 98 | ― | ― | * | * | ||
PEEP/EPAP | 100 | ― | ― | * | * | ||
Pressure-regulated Volume Control (PRVC) | 81 | ― | ― | * | N/A | ||
PS/IPAP | 100 | ― | ― | * | * | ||
SIMV (Volume) / (Pressure) | 93 | ― | ― | * | * | ||
Weaning protocols | 96 | ― | ― | * | NRC | ||
Pathophysiology and presenting features, likely medical management and implications for physiotherapy for a range of conditions including | |||||||
Acute coronary syndrome (e.g. angina, STEMI, NSTEMI) | 100 | ― | ― | * | * | ||
Acute lung injury/acute respiratory distress syndrome (ARDS) | 98 | ― | ― | * | * | ||
Burns (cutaneous/inhalational) | 81 | ― | ― | NRC | NE | ||
Chest trauma | 93 | ― | ― | * | * | ||
Community acquired/nosocomial/hospital-acquired pneumonia (including VAP) | 100 | ― | ― | * | * | ||
Guillain-Barre Syndrome | 76 | ― | ― | * | * | ||
Heart failure | 100 | ― | ― | * | * | ||
Hepatitis | 72 | ― | ― | NRC | NE | ||
ICU-acquired weakness (ICU-AW) | 100 | ― | ― | * | * | ||
Immunocompromise | 65 | 85 | ― | * | * | ||
Intracerebral hemorrhage/Subarachnoid hemorrhage | 100 | ― | ― | * | * | ||
Metabolic/electrolyte disturbances | 98 | ― | ― | * | NRC | ||
Multi-organ failure/MODS | 94 | ― | ― | * | * | ||
Multi-trauma | 93 | ― | ― | * | NRC | ||
Obstructive respiratory disease (e.g. asthma, COPD) | 100 | ― | ― | * | * | ||
Pancreatitis | 76 | ― | ― | * | NRC | ||
Pleural effusion | 98 | ― | ― | * | * | ||
Post-abdominal surgery | 98 | ― | ― | * | * | ||
Post-cardiac surgery | 94 | ― | ― | * | NRC | ||
Post-surgery other (e.g. orthopaedic, vascular) | 94 | ― | ― | * | N/A | ||
Post-thoracic surgery | 100 | ― | ― | * | NRC | ||
Renal failure (acute and chronic) | 100 | ― | ― | * | * | ||
Respiratory failure (Type I and II) | 100 | ― | ― | * | * | ||
Restrictive respiratory disease (e.g. pulmonary fibrosis, kyphoscoliosis) | 98 | ― | ― | * | * | ||
Shock (cardiogenic) | 98 | ― | ― | * | * | ||
Shock (septic) | 94 | ― | ― | * | * | ||
Spinal cord injury | 96 | ― | ― | * | * | ||
Suppurative lung disease (e.g. cystic fibrosis, bronchiectasis) | 74 | ― | ― | * | * | ||
Systemic inflammatory response syndrome (SIRS) | 89 | ― | ― | * | * | ||
Thromboembolic disease (e.g. deep vein thrombosis, pulmonary embolus) | 100 | ― | ― | * | * | ||
Thrombotic cerebrovascular accident | 96 | ― | ― | * | N/A | ||
Traumatic brain injury | 94 | ― | ― | * | * | ||
A physiotherapist can accurately/independently (assess and) interpret | |||||||
Readings from clinical monitoring including | |||||||
Advanced ECGs (i.e. conduction block, 12-lead ECG) | 80 | ― | ― | NE | NRC | ||
Basic ECGs (i.e. sinus rhythm/tachycardia/bradycardia, atrial fibrillation, atrial flutter, ventricular tachycardia, ventricular fibrillation, asystole, PVCs) | 98 | ― | ― | * | * | ||
Blood pressure (systolic, diastolic, and mean arterial blood pressure) | 100 | ― | ― | * | * | ||
Body temperature | 100 | ― | ― | * | * | ||
Central venous pressure | 94 | ― | ― | * | NRC | ||
End tidal carbon dioxide | 83 | ― | ― | * | * | ||
Fluid intake and output | 96 | ― | ― | * | * | ||
Heart rate | 100 | ― | ― | * | * | ||
Nutritional status including feed administration, volume and type | 85 | ― | ― | NE | NE | ||
SpO2/Pulse oximetry | 100 | ― | ― | * | * | ||
Findings from laboratory investigations including | |||||||
Albumin | 94 | ― | ― | NE | NE | ||
Blood glucose levels | 96 | ― | ― | * | * | ||
C-reactive protein (CRP) | 100 | ― | ― | NRC | * | ||
Creatinine kinase (CK) | 98 | ― | ― | NRC | NE | ||
Hematocrit | 83 | ― | ― | NE | NE | ||
Hemoglobin | 100 | ― | ― | * | * | ||
Liver function tests (e.g. ALT, LDH, Bilirubin) | 93 | ― | ― | NE | NE | ||
Neutrophil counts | 80 | ― | ― | NRC | NE | ||
Platelets, APTT (activated partial thromboplastin time), INR (international normalized ratio) | 87 | ― | ― | * | * | ||
Renal function tests (e.g. urea, creatinine) | 93 | ― | ― | * | NRC | ||
Respiratory function tests (e.g. FEV1, FVC etc.) | 98 | ― | ― | * | NRC | ||
Troponin | 76 | ― | ― | * | * | ||
White cell count (WCC) | 98 | ― | ― | * | * | ||
Findings from imaging investigations (excluding the imaging report) including | |||||||
Chest radiographs (CXR) | 94 | ― | ― | * | * | ||
CT - Brain imaging | 74 | ― | ― | NE | NE | ||
CT - Chest imaging | 81 | ― | ― | NE | NE | ||
MRI - Brain | 74 | ― | ― | NE | NE | ||
Skeletal X-rays | 81 | ― | ― | NRC | NE | ||
Ultrasound - Chest | 74 | ― | ― | NE | NE | ||
Results from neurological equipment/examinations and functional tests including | |||||||
Ability to interpret a delirium assessment (e.g. the CAM-ICU) | 96 | ― | ― | NRC | N/A | ||
Ability to perform a delirium assessment (e.g. the CAM-ICU) | 83 | ― | ― | NE | NE | ||
An ability to interpret a Glasgow Coma Score (GCS) | 100 | ― | ― | * | * | ||
An ability to interpret an assessment of cranial nerve function | 93 | ― | ― | NRC | NE | ||
An ability to interpret an assessment of sedation levels (e.g. Ramsey Sedation Scale, Richmond Agitation-Sedation Scale) | 100 | ― | ― | * | NRC | ||
An ability to perform a Glasgow Coma Score (GCS) | 93 | ― | ― | NRC | NE | ||
An ability to perform a neurological examination of motor and sensory functions (e.g. light touch, pain, ASIA score) | 98 | ― | ― | * | NRC | ||
An ability to perform an assessment of cranial nerve function | 93 | ― | ― | NE | NE | ||
An ability to perform an assessment of sedation levels | 98 | ― | ― | NE | NE | ||
Intra-cranial pressure (ICP) monitors (intra-parenchymal, intra-ventricular) and cerebral perfusion pressure (CPP) | 52 | 74 | ― | * | NRC | ||
Indices from blood gas measurement including | |||||||
A-a gradient | 81 | ― | ― | NE | NE | ||
Base excess | 76 | ― | ― | * | * | ||
HCO3 | 91 | ― | ― | * | * | ||
Lactate | 87 | ― | ― | NE | NRC | ||
PaCO2 | 100 | ― | ― | * | * | ||
PaO2, SpO2, SaO2 | 100 | ― | ― | * | * | ||
PaO2/FiO2 ratio | 100 | ― | ― | * | NE | ||
pH | 98 | ― | ― | * | * | ||
Venous blood gas interpretation (including SvO2) | 74 | ― | ― | NRC | NE | ||
(assess and interpret) Mechanical ventilation settings/measurements including | |||||||
Breath types (spontaneous, mandatory, assisted) | 100 | ― | ― | * | * | ||
Maximum inspiratory pressure (MIP) measurements | 63 | 72 | ― | NE | NE | ||
Peak inspiratory pressure | 93 | ― | ― | * | * | ||
Respiratory rate | 100 | ― | ― | * | * | ||
Static and/or dynamic lung compliance measures | 61 | 72 | ― | NE | NE | ||
The level of FiO2 | 100 | ― | ― | * | * | ||
The level of PEEP | 100 | ― | ― | * | * | ||
The level of PS | 98 | ― | ― | * | * | ||
Tidal volume | 100 | ― | ― | * | * | ||
A physiotherapist can | |||||||
Perform and accurately interpret the results of common respiratory examinations including | |||||||
Auscultation | 100 | ― | ― | * | * | ||
Observation of respiratory rate | 100 | ― | ― | * | * | ||
Palpate the chest wall | 94 | ― | ― | * | * | ||
Patterns of breathing | 100 | ― | ― | * | * | ||
Assess | |||||||
The effectiveness/quality of a patient's cough (on or off mechanical ventilation) | 96 | ― | ― | * | * | ||
Provide the following techniques, including an understanding of indications, contraindications, evidence for the technique, and progressions | |||||||
ACBT [breathing control, thoracic expansion and FET] | 83 | * | * | ||||
Assisted coughing - chest wall | 85 | ― | ― | * | * | ||
Assisted coughing - subcostal thrusts for spinal cord injuries | 54 | 74 | ― | * | NRC | ||
Bed exercises (e.g. passive - active - resisted range of motion exercises) | 100 | ― | ― | * | * | ||
Braces | 74 | ― | ― | NE | NE | ||
Directed coughing/instructing the patient to cough effectively | 96 | ― | ― | * | * | ||
Electrical stimulation (e.g. for isolated muscle activation to prevent muscle wasting, such as neuromuscular/functional electrical stimulation) | 78 | ― | ― | NE | NE | ||
Humidification | 76 | ― | ― | * | * | ||
Inexsufflator (Cough Assist) | 65 | 70 | ― | NE | * | ||
Inspiratory muscle training | 78 | ― | ― | NE | NE | ||
Mobilization of non-ventilated patient (e.g. sitting on edge of bed, stand, hoist or slide transfer to chair, march on spot, walk, use of gait aids) | 100 | ― | ― | * | * | ||
Mobilization of ventilated patient (e.g. sitting on edge of bed, stand, hoist or slide transfer to chair, march on spot, walk, use of gait aids) | 98 | ― | ― | * | * | ||
NIV/BiPAP - for use during exercise or mobilization including initiation and titration of | 69 | 70 | ― | NRC | NE | ||
Patient positioning for prevention of pressure ulcers, management of tone, maintenance of musculoskeletal function | 100 | ― | ― | * | * | ||
Patient positioning for respiratory care - including use of side lie, sitting upright, postural drainage (modified or head down tilt) | 100 | ― | ― | * | * | ||
Patient prone positioning in severe respiratory failure/acute lung injury | 87 | ― | ― | NRC | NRC | ||
Pursed lip breathing | 98 | ― | ― | * | N/A | ||
Suction via a tracheal tube (Endotracheal tube, tracheostomy, minitracheostomy) | 67 | 72 | ― | * | * | ||
Supported coughing | 98 | ― | ― | * | * | ||
Treadmill, cycle ergometry (e.g. Motomed) or stationary bike | 87 | ― | ― | NRC | NE | ||
A physiotherapist can | |||||||
Complete musculoskeletal and/or functional assessments including | |||||||
Ability to assess tone (e.g. utilizing a Modified Ashworth Scale) and reflexes | 100 | ― | ― | * | NRC | ||
Deep vein thrombosis screening (i.e. color, temperature, touch, swelling, Homan's test) | 93 | ― | ― | * | * | ||
Dynamometry | 81 | ― | ― | NRC | NE | ||
Manual muscle testing (e.g. MRC scale) | 98 | ― | ― | * | * | ||
Objective measures of cardiopulmonary exercise tolerance (e.g. 6-minute walk test; incremental shuttle walk test) | 87 | ― | ― | NRC | NE | ||
Objective measures of physical function [e.g. the Physical Function ICU Test (PFIT), Timed Up and Go Test (TUG), 6MWT, De-Morton Mobility Index (DEMMI) ] | 93 | ― | ― | * | NE | ||
Objective measures of quality of life (e.g. Short Form 36, EQ-5D, AQoL) | 72 | ― | ― | NE | NE | ||
Peripheral edema | 96 | ― | ― | * | * | ||
Range of motion | 100 | ― | ― | * | * | ||
Appropriately | |||||||
Be aware of inotropes and implications for physiotherapy treatment | 100 | ― | ― | * | N/A | ||
Be aware of sedation and implications for physiotherapy treatment | 98 | ― | ― | * | N/A | ||
Liaise with medical/nursing staff to increase/decrease inotropes to achieve physiotherapy goals | 85 | ― | ― | * | N/A | ||
Liaise with medical/nursing staff to increase/decrease sedation to achieve physiotherapy goals | 94 | ― | ― | * | N/A | ||
A physiotherapist can | |||||||
Assess and interpret ventilator waveforms | 89 | ― | ― | NE | N/A | ||
Determine the appropriateness of a patient for extubation | 83 | ― | ― | NRC | NRC |